Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Subscribe To Our Newsletter & Stay Updated